01—Abstract
Summary
Summary of the 8-K filed May 11, 2022. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. announced a significant change in its Chief Financial Officer role through an 8-K filing on May 11, 2022.
Jorge Gomez, the former CFO, departed the company, effective immediately. His departure is notable given its timing with the public disclosure of an internal investigation into financial reporting matters at his former employer, Dentsply Sirona Inc. While Gomez will receive severance benefits including 12 months of salary and COBRA coverage, he will forfeit certain previously disclosed benefits like his signing bonus and equity awards. In response to this unexpected vacancy, Moderna has appointed David Meline, who recently retired from the CFO position, to continue serving in the role effective May 11, 2022.
Meline's compensation package remains largely consistent with his previous role, including a $700,000a annual salary and target annual incentive. Importantly, the Compensation Committee has approved continued eligibility for vesting of his 2022 equity awards and an extended exercise period for vested stock options, reflecting his continued critical role in the company's financial operations.
02—Key points
Key Highlights
- Moderna's Chief Financial Officer, Jorge Gomez, has departed the company, effective immediately.
- Mr. Gomez's departure follows a public disclosure of an internal investigation into financial reporting at his former employer, Dentsply Sirona Inc.
- In connection with his departure, Mr. Gomez will receive 12 months of salary ($700,000) and 12 months of COBRA coverage, but will forfeit other benefits.
- David Meline, the recently retired CFO, will continue as CFO, effective May 11, 2022.
- Mr. Meline's compensation includes a $700,000 annual salary and a target annual incentive of 90% of base salary.
- Mr. Meline's 2022 equity awards will continue to be eligible for vesting, and he will have an extended period to exercise vested stock options.
- This executive transition introduces a degree of uncertainty regarding financial leadership, although Meline's reappointment provides immediate continuity.
03—Questions
Frequently Asked Questions
What is the reason for Jorge Gomez's departure as CFO?
While the filing states Jorge Gomez departed effectively immediately, it notes this follows the public disclosure of an internal investigation into financial reporting matters at his former employer, Dentsply Sirona Inc. The filing does not explicitly state this investigation is the direct cause of his departure from Moderna, but it is presented as a significant contextual event.
What financial implications does Jorge Gomez's departure have for Moderna?
The direct financial implications are primarily the severance package provided to Mr. Gomez, totaling $700,000 in salary and 12 months of COBRA coverage. His departure also means the forfeiture of his signing bonus, relocation reimbursements, bonus eligibility, and new hire equity awards that were previously disclosed. Operationally, the company will incur costs and efforts related to executive transition, although the immediate reappointment of David Meline mitigates significant disruption.
What is David Meline's new compensation package as he continues as CFO?
David Meline will continue to receive his prior benefits, including an annual salary of $700,000. He is also eligible for an annual incentive target of 90% of his base salary, contingent on achieving performance goals. Additionally, his 2022 equity awards will remain eligible for full vesting, and he will be granted 12 months from his last date of service to exercise any vested but unexercised stock options.
Does David Meline's continued service as CFO indicate any concerns about Moderna's financial reporting?
The filing itself does not suggest any concerns about Moderna's financial reporting. David Meline's continued service is presented as a measure to ensure continuity in the CFO role following Jorge Gomez's immediate departure. His reappointment, along with the adjusted terms for his equity awards, suggests the company values his expertise and experience during this transition period.
04—Continue